Nexalin Technology (NASDAQ:NXL – Get Free Report) and SiBone (NASDAQ:SIBN – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.
Earnings & Valuation
This table compares Nexalin Technology and SiBone”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nexalin Technology | $217,155.00 | 15.87 | -$8.22 million | ($14.41) | -0.33 |
| SiBone | $200.93 million | 4.22 | -$18.90 million | ($0.34) | -56.29 |
Institutional and Insider Ownership
0.6% of Nexalin Technology shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 16.9% of Nexalin Technology shares are owned by insiders. Comparatively, 4.0% of SiBone shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings and target prices for Nexalin Technology and SiBone, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nexalin Technology | 1 | 1 | 0 | 0 | 1.50 |
| SiBone | 1 | 0 | 6 | 0 | 2.71 |
SiBone has a consensus target price of $24.17, indicating a potential upside of 26.28%. Given SiBone’s stronger consensus rating and higher probable upside, analysts clearly believe SiBone is more favorable than Nexalin Technology.
Profitability
This table compares Nexalin Technology and SiBone’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nexalin Technology | -4,141.94% | -278.24% | -218.42% |
| SiBone | -6.85% | -8.23% | -6.07% |
Volatility and Risk
Nexalin Technology has a beta of 4.08, suggesting that its stock price is 308% more volatile than the S&P 500. Comparatively, SiBone has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.
Summary
SiBone beats Nexalin Technology on 9 of the 14 factors compared between the two stocks.
About Nexalin Technology
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
About SiBone
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
